Nitrogen (N) modification of carbon nanomaterial, which plays a critical role in improving platinum (Pt) performance, has shown fascinating applications.
We identified DKK1 as a possible marker of a cisplatin-refractory phenotype and as a potential novel therapeutic target to improve platinum response of NSCLC cells.
Consequently, the six-coordinate (Pt(IV)) class of Pt drugs were developed to improve platinum efficacy by (i) increasing stability, (ii) reducing reactivity, (iii) increasing lipophilicity, and (iv) nuclear targeting.
Such studies were conducted with the aim of further improving platinum-based chemotherapy and minimising the emergence of drug resistance.
In metastatic lung cancer, survival is modestly improved with platinum-based palliative chemotherapy, but, more important it can help to reduce tumour-related symptoms, and lead to improved quality of life (QoL).
Two general approaches have been pursued to address drug resistance: development of new therapeutics, and drug combinations that improve standard platinum and/or taxane based chemotherapy.
It was also found that the presence of platinum improved the nickel reduction in comparison to the presence of nickel only [40].
Platinum improved catalyst stability by preventing formation of coke precursors on strong acid site of sulfated zirconium.
At low current densities, performance is mainly improved by increasing platinum loading to values above 1 mg cm−2, moderate values of electrolyte volume fraction, 0.5, and low porosity, 0.1.
Konstaninopoulos et al (2010) reported improved responsiveness to platinum in a cohort of sporadic EOC patients with a BRCAness profile defined by gene expression analysis.
